A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic
A phase 2 trial of Encorafenib, Cetuximab, Pembrolizumab in colorectal cancer, run by Pfizer, active and no longer recruiting.
Overview
A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer is a phase 2 interventional study registered as NCT05217446 by Pfizer, with 108 participants enrolled, started 2022-07-11 and due to reach its primary completion in 2026-06-19. Interventions recorded: Encorafenib, Cetuximab, Pembrolizumab. Conditions listed: Metastatic Colorectal Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
Shares Encorafenib, Pfizer (incl. Seagen), Pembrolizumab.
- TrialStudy of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)
Shares Cetuximab, Pembrolizumab, Colorectal cancer.
- PersonRyan B. Corcoran
Shares Encorafenib, Cetuximab, Colorectal cancer.
- TrialPhase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)
Shares Cetuximab, Colorectal cancer.
- TrialThis is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lu
Shares Pfizer (incl. Seagen), Pembrolizumab.
- TrialStudy for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies
Shares Cetuximab, Pfizer (incl. Seagen).
- TrialSymbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Shares Pfizer (incl. Seagen), Colorectal cancer.
- TrialA Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advance
Shares Cetuximab, Pembrolizumab, Colorectal cancer.